Beta-Receptor Blocking Treatment in Portal Hypertension

References

• Lebrec D, Nouel O, Corbic M, Benhamou J-P. Propranolol—a medical treatment for portal hypertension?. Lancet 1980; 2: 180–182
   PubMed Web of Science ®Google Scholar
• Lebrec D, Nouel O, Bernuau J, Bouygues M, Rueff B, Benhamou J-P. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet 1981; 1: 920–921
   PubMed Web of Science ®Google Scholar
• Lebrec D, Poynard T, Bernuau J, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4: 355–358
   PubMed Web of Science ®Google Scholar
• Conn H O. Propranolol in the treatment of portal hypertension: A caution [Editorial]. Hepatology 1982; 2: 641–644
   PubMedGoogle Scholar
• Burroughs A K, Jenkins W J, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983; 309: 1539–1542
   PubMed Web of Science ®Google Scholar
• Villeneuve J-P, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology 1986; 6: 1239–1243
   PubMed Web of Science ®Google Scholar
• Queuniet A M, Czernichow P, Lerebours E, Ducrotte P, Tranvouez J L, Colin R. Etude con-trôllée du propranolol dans la prevention des réci-dives hémorragiques chez les patients cirrhotiques. Gastroenterol Clin Biol 1987; 11: 41–47
   PubMedGoogle Scholar
• Mills P R, Garden O J, Birnie G G, Carter D C. Propranolol in the prevention of further variceal hemorrhage in cirrhosis. Gastroenterology 1987; 92: 1755
   Google Scholar
• Marbet U A, Straumann A, Gyr K E, et al. Reduction in early recurrence of variceal bleeding by propranolol. Scand J Gastroenterol 1988; 23: 369–374
   PubMed Web of Science ®Google Scholar
• Sheen I S, Chen T Y, Liaw Y F. Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver 1989; 9: 1–5
   PubMedGoogle Scholar
• Colombo M, deFranchis R, Tommasini M, Sangio-vanni A, Dioguardi N. β-Blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology 1989; 9: 433–438
   PubMed Web of Science ®Google Scholar
• Kiire C F. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. Br Med J 1989; 298: 1363–1365
   PubMedGoogle Scholar
• Burroughs A K, Mezzanotte G, Phillips A, McCormick P A, McIntyre N. Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 1989; 9: 801–807
   PubMed Web of Science ®Google Scholar
• Infante-Rivard C, Esnaola S, Villeneuve J-P. Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a meta-analysis. Gastronterology 1989; 96: 1087–1092
   PubMed Web of Science ®Google Scholar
• Fleig W E, Stange E F, Hunecke R, et al. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology 1987; 7: 355–361
   PubMed Web of Science ®Google Scholar
• Alexandrino P T, Alves M M, Correia J P. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. A prospective, randomized controlled trial. J Hepatol 1988; 7: 175–185
   PubMedGoogle Scholar
• Koch H, Henning H, Grimm H, Soehendra V. Prophylactic sclerosing of esophageal varices —results of a prospective controlled study. Endoscopy 1986; 18: 40–43
   PubMedGoogle Scholar
• Santangelo W C, Dueno M I, Estes B L, Krejs G J. Prophylactic sclerotherapy of large esophageal varices. N Engl J Med 1988; 318: 814–818
   PubMed Web of Science ®Google Scholar
• Westaby D, Melia W, Hegarty J, Gimson A ES, Stellon A J, Williams R. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology 1986; 6: 673–675
   PubMed Web of Science ®Google Scholar
• Vickers C, Rhodes J, Hillenbrand P, et al. Prospective controlled trial of propranolol and sclerotherapy for prevention of rebleeding from oesophageal varices. Gut 1987; 28: A1328
   Google Scholar
• O'Connor K W, Lehman G, Yune H, et al. Comparison of three nonsurgical treatments for bleeding esophageal varices. Gastroenterology 1989; 96: 899–906
   PubMedGoogle Scholar
• Jensen L S, Krarup N. Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. Scand J Gastroenterol 1989; 24: 339–345
   PubMed Web of Science ®Google Scholar
• Westaby D, MacDougall B RD, Williams R. Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. Hepatology 1985; 5: 827–830
   PubMed Web of Science ®Google Scholar
• Pascal J-P, Cales P, and a multicenter group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317: 856–861
   PubMed Web of Science ®Google Scholar
• Bosch J, Groszmann R J, Grace N, et al. Propranolol in the prevention of the first hemorrhage from esophageal varices: results of a randomized, double-blind, cooperative clinical trial. J Hepatol 1988; 7(suppl 1)S12
   Google Scholar
• The Italian multicenter project for propranolol in prevention of bleeding: propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. J Hepatol 1989; 9: 75–83
   PubMed Web of Science ®Google Scholar
• Idéo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988; 8: 6–9
   PubMed Web of Science ®Google Scholar
• Lebrec D, Poynard T, Capron J-P, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. J Hepatol 1988; 7: 118–125
   PubMed Web of Science ®Google Scholar
• Tarver D, Walt R P, Dunk A A, Jenkins W J, Sherlock S. Precipitation of hepatic encephalopathy by propranolol in cirrhosis. Br Med J 1983; 287: 585
   PubMedGoogle Scholar
• Wiesner R H. Does propranolol precipitate hepatic encephalopathy?. J Clin Gastroenterol 1986; 8: 74–76
   PubMedGoogle Scholar
• Van Buuren H R, van der Velden P C, Koorevaar G, Silberbusch J. Propranolol increases arterial ammonia in liver cirrhosis. Lancet 1982; 2: 951–952
   PubMedGoogle Scholar
• Arthur M JP, Tanner A R, Patel C, George C F, Wright R. Portal hypertension, propranolol, and hepatic encephalopathy. Lancet 1982; 2: 879–880
   Google Scholar
• Reiding P. Risk of hepatic encephalopathy in patients taking propranolol for portal hypertension. Lancet 1982; 2: 550
   Google Scholar
• Dunk A A, Moore J, Symon A, et al. The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 1988; 2: 143–151
   PubMedGoogle Scholar
• Calès P, Pierre-Nicolas M, Guell A, et al. Propranolol does not alter cerebral blood flow and functions in cirrhotic patients without previous hepatic encephalopathy. Hepatology 1989; 9: 439–442
   PubMedGoogle Scholar
• Bataille C, Bercoff E, Pariente E A, Valla D, Lebrec D. Effects of propranolol on renal blood flow and renal function in patients with cirrhosis. Gas-troenterology 1984; 86: 129–133
   PubMedGoogle Scholar
• Meacci E, LaVilla G, Laffi G, et al. Systemic hemo-dynamics, renal and platelet function during chronic propranolol administration in patients with compensated cirrhosis. Liver 1987; 7: 110–115
   PubMedGoogle Scholar
• Bernardi M, DePalma R, Trevisani F, et al. Renal function and effective β-blockade in cirrhosis with ascites. Relationship with baseline sympathoad-renergic tone. J Hepatol 1989; 8: 279–286
   PubMedGoogle Scholar
• Hayes P C, Stewart W W, Bouchier I AD. Influence of propranolol on weight and salt homeostasis in chronic liver disease. Lancet 1984; 2: 1064–1068
   PubMedGoogle Scholar
• Scemama-Clergue J, Piquiet J, Clerici C, Harf A, Dhumeaux D. Effects of propranolol on pulmonary gas exchange in patients with cirrhosis. J Hepatol 1989; 9: 234–239
   PubMedGoogle Scholar
• Bernardi M, DePalma R, Trevisani F, et al. ‘Low T3 syndrome’ in cirrhosis: effect of β-blockade. Am J Gastroenterol 1989; 84: 727–731
   PubMedGoogle Scholar
• Braillon A, Jirón M I, Valla D, Calès P, Lebrec D. Effect of propranolol on hepatic blood flow in patients with cirrhosis. Clin Pharmacol Ther 1985; 37: 376–380
   PubMedGoogle Scholar
• Mastai R, Bosch J, Bruix J, Navasa M, Kravetz D, Rodés J. β-blockade with propranolol and hepaticartery blood flow in patients with cirrhosis. Hepatology 1989; 10: 269–272
   PubMedGoogle Scholar
• Hayes P C, Bouchier I AD. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease. Am J Gastroenterol 1989; 84: 723–726
   PubMedGoogle Scholar
• Hillon P, Lebrec D, Múnoz C, Jungers M, Goldfarb G, Benhamou J-P. Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528–531
   PubMed Web of Science ®Google Scholar
• Mills P R, Rae A P, Farah D A, Russell R I, Lorimer A R, Carter D C. Comparison of three adreno-receptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25: 73–78
   PubMed Web of Science ®Google Scholar
• Westaby D, Bihari D J, Gimson A ES, Crossley I R, Williams R. Selective and nonselective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 1984; 25: 121–124
   PubMed Web of Science ®Google Scholar
• Vorobioff J, Picabea E, Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 648–653
   PubMed Web of Science ®Google Scholar
• Valla D, Jiron M I, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987; 5: 144–148
   PubMedGoogle Scholar
• Jungers M, Hillon P, Lebrec D. Degré de l'hypertension portale et risque de récidive hémorrhagique chez les malades atteints de cirrhose. Gastroenterol Clin Biol 1982; 6: 318–320
   PubMedGoogle Scholar
• Bosch J, Groszmann R J. Measurement of azygos venous blood flow by a continuous thermal dilution technique: an index of blood flow through gastro-esophageal collaterals in cirrhosis. Hepatology 1984; 4: 424–429
   PubMed Web of Science ®Google Scholar
• Calés P, Braillon A, Jiron M, Lebrec D. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. J Hepatol 1984; 1: 37–46
   Web of Science ®Google Scholar
• Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200–1205
   PubMed Web of Science ®Google Scholar
• Zoli M, Marzocchi A, Marchesini G, Marrozini C, Dondi C, Pisi E. Atenolol in portal hypertension—a haemodynamic study. Ital J Gastroenterol 1985; 17: 252–257
   Google Scholar
• Braillon A, Lee S S, Valla D, Geoffroy P, Sauvanet J P, Lebrec D. Comparative haemodynamic effects of betaxolol and propranolol in patients with cirrhosis. Scand J Gastroenterol 1988; 23: 691–695
   PubMed Web of Science ®Google Scholar
• Bützow G H, Remmecke J, Bräuer A. Metoprolol in portal hypertension. A controlled study. Klin Wochenschr 1982; 60: 1311–1314
   PubMedGoogle Scholar